President Trump announced that the U.S. government will provide GLP-1 drugs (weight-loss and diabetes medications) to Medicare patients. The statement signals potential government coverage expansion for these expensive medications.

• •Trump said the U.S. will provide GLP-1 drugs to Medicare patients
• •Announcement signals potential federal coverage expansion for GLP-1s

The FDA is proposing to stop pharmacies from making bulk copies of GLP-1 drugs (weight-loss and diabetes medications). This change could force more patients to buy expensive brand-name versions instead of cheaper compounded alternatives.

• •FDA proposing to end mass pharmacy compounding of GLP-1 drugs
• •Patients could be pushed toward brand-name versions
• •Compounded alternatives have been the cheaper option

The FDA is proposing to block pharmacies from making cheaper copies of GLP-1 weight-loss drugs, which would help Eli Lilly and Novo Nordisk sell more of their brand-name versions. This rule change could force patients to buy the expensive official medicines instead of lower-cost pharmacy-made alternatives.

• •FDA proposing to block pharmacies from compounding GLP-1 weight-loss drugs
• •Rule would favor branded versions from Eli Lilly and Novo Nordisk
• •Patients would lose access to lower-cost pharmacy-made alternatives

• •Lilly and Novo Nordisk shares dipped on the news
• •A proposed Medicare coverage pilot for GLP-1s has been thrown off balance

A court partially dismissed Eli Lilly's lawsuit against Empower Pharmacy, a Houston compounding pharmacy that makes GLP-1 drugs (weight-loss and diabetes medications). The case involves a dispute over whether pharmacies can legally make cheaper copies of these drugs.

• •Court partially dismissed Eli Lilly's lawsuit against Empower Pharmacy
• •Empower is a Houston compounding pharmacy producing GLP-1 drugs
• •Case centers on legality of compounded copies of GLP-1 medications

• •Headline frames FDA GLP-1 compounding ruling as potentially favoring Hims & Hers

The FDA sent a warning letter to a GLP-1 drug maker after the company refused to let FDA inspectors visit their facility. Warning letters are serious regulatory actions that signal the agency found significant problems with how a drug is made or sold.

• •FDA issued a warning letter to a GLP-1 drug manufacturer
• •Company refused FDA inspectors access to its facility
• •Warning letters indicate significant manufacturing or sales problems

A judge threw out part of Eli Lilly's lawsuit against Empower Pharmacy, a Houston company that makes GLP-1 drugs (weight-loss and diabetes medicines) without a brand name. The decision limits how much of Eli Lilly's case can move forward in court.

• •Judge dismissed part of Eli Lilly's GLP-1 lawsuit against Empower Pharmacy
• •Empower is a Houston-based compounder of GLP-1 drugs
• •Ruling limits scope of Lilly's case going forward

Researchers at Penn Medicine found that stopping and restarting GLP-1 drugs (a type of weight-loss medicine) may make them work less well than if you keep taking them without stopping. This suggests people trying to use these drugs on-and-off to save money or manage side effects might not get the full weight-loss benefit.

• •Penn Medicine researchers studied stopping and restarting GLP-1 drugs
• •Findings suggest reduced effectiveness vs. continuous use
• •Relevant to patients cycling drugs for cost or side-effect reasons

• •FDA proposal flagged as supportive of Novo Nordisk GLP-1 exclusivity
• •Framed as a potential tailwind for Novo Nordisk valuation

• •Novo Nordisk announced a list price cut on its GLP-1.
• •Mercer published guidance on what plan sponsors should watch next.

• •Barclays cites Lilly's strong GLP-1 results as supportive of Novo Nordisk's outlook
• •Note frames GLP-1 category growth as benefiting both incumbents

• •Procedure for type 2 diabetes reported to help maintain weight loss after GLP-1 discontinuation

Pfizer's GLP-1 weight-loss drug (a medicine that helps people lose weight) is now available for people to pre-order in China. This is the company's first move to sell this type of drug in the Chinese market.

• •Pfizer GLP-1 weight-loss drug available for pre-order in China
• •First Pfizer move to sell a GLP-1 in the Chinese market

A company posted fake customer testimonials while claiming to sell GLP-1 weight-loss drugs, but had no actual pharmacy license. The FDA issued a warning about the fraudulent operation.

• •FDA issued a warning over a fraudulent GLP-1 weight-loss seller
• •Operator posted fake customer testimonials
• •Company had no actual pharmacy license

• •HSS studies provide early evidence on perioperative considerations for patients on GLP-1 medications

• •Cora Health expanding telehealth access to GLP-1 medications
• •Service availability cited across 44 states